FoxP1 is a transcriptional repressor associated with cancer cachexia that induces skeletal muscle wasting and weakness.
Daria NeyroudRachel L NosackaChandler S CallawayJose G TrevinoHui HuSarah M JudgeAndrew R JudgePublished in: Journal of cachexia, sarcopenia and muscle (2021)
In summary, we identify FoxP1 as a novel repressor of skeletal muscle gene expression that is increased in cancer cachexia, whose up-regulation is sufficient to induce skeletal muscle wasting and weakness, and required for the normal wasting response to cancer.